

PRESS INFORMATION



CytoTools

Patent protection extended for DermaPro®

- Patent for preparation for wound healing granted in Japan
- Clinical research continues on product with diverse application possibilities

Darmstadt, 20. July 2011. CytoTools AG has reached another milestone on the way to the market launch of their active substance *DermaPro®*: The Company received confirmation from the Japanese patent office that patent protection has been granted in Japan. This protective right augments the fundamental protection of the technology exclusively used by DermaTools Biotech GmbH within the scope of wound treatment in the large pharmaceutical markets Europe, USA and Japan. Thus the patent situation of *DermaPro®* has received another significant extension, a fact which will be reflected in the licence negotiations with the pharmaceuticals industry for the worldwide use of the product in the individual markets.

DermaPro® is an active substance developed by DermaTools Biotech GmbH which can be used for the treatment of chronic wounds and burns as well as infected wounds. Currently, two parallel clinical trials are in progress with DermaPro® in which the active substance, which accelerates wound healing significantly, is being applied to the indication diabetic foot. The studies are now in phases IIb (Germany) and III (India).

This information contains certain forward-looking statements. These reflect the opinion of CytoTools at the date of this information release. The results which are actually achieved by CytoTools in the future may differ significantly from the statements made herein. CytoTools is not obliged to revise or update such forward-looking statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: 52% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

PRESS INFORMATION



CytoTools

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Janis Fischer
Unter den Eichen 7
D-65195 Wiesbaden
Tel.: +49-611-205855-64
Fax: +49-611-205855-66
E-Mail: fischer@cometis.de